our constellation

Our lead product candidate, topical CGS-200-5, is being developed for the management of pain due to osteoarthritis (OA) of the knee.  It has already successfully completed a Phase 2 clinical study for pain due to knee OA and is Phase 3 ready.  PRL-02 utilizes an innovative and patented prodrug of a known active pharmaceutical ingredient (API) and clinical studies will begin in 2Q 2021.